Loading...
•
Mar 31
Ekso Bionics Q1 2025 Earnings Report
Ekso Bionics reported a decrease in revenue and net loss for the first quarter of 2025, while improving its operating cash burn.
Key Takeaways
Ekso Bionics reported revenue of $3.4 million for the first quarter of 2025, a decrease from $3.8 million in the same period of 2024. The net loss applicable to common stockholders was $2.9 million, or $0.12 per basic and diluted share, an improvement from a net loss of $3.4 million, or $0.20 per basic and diluted share, in the prior year. The company also improved its operating cash burn by 43%.
Revenue for Q1 2025 was $3.4 million, down from $3.8 million in Q1 2024, primarily due to lower sales of legacy EksoNR devices.
Net loss improved to $2.9 million ($0.12 per share) in Q1 2025 from $3.4 million ($0.20 per share) in Q1 2024.
Gross profit was $1.8 million (53.5% margin) in Q1 2025, compared to $2.0 million (51.9% margin) in Q1 2024.
Operating cash burn improved by 43% in Q1 2025, with $2.0 million of net cash used in operations compared to $3.5 million in Q1 2024.
Ekso Bionics
Ekso Bionics
Forward Guidance
Ekso Bionics anticipates increased contribution from its Personal Health products in 2025 due to new partnerships, which are expected to significantly expand access to Ekso Indego Personal devices.
Positive Outlook
- Significant expansion of access to Ekso Indego Personal through new partnerships.
- Partnership with National Seating & Mobility (NSM) as exclusive Ekso Indego Personal device distributor in the U.S. complex rehabilitation technology (CRT) industry.
- Partnership with Bionic Prosthetics & Orthotics Group (Bionic P&O) as its first Ekso Indego Personal device distributor in the orthotics and prosthetics industry.
- NSM's network of over 180 locations and more than 2,400 team members supporting over 250,000 mobility solutions annually.
- Bionic P&O's operation across 12 states as an ABC accredited independent clinical practice group.
Challenges Ahead
- The company's ability to obtain adequate financing to fund and grow operations and develop/enhance technology.
- Challenges in successfully collaborating with neuro-rehabilitation facilities, physicians, and DMEs for CMS reimbursements.
- Inability to obtain future CMS reimbursements in a timely manner or at expected levels.
- Failure to achieve broad market acceptance of products or ineffective sales/marketing efforts.
- Risks related to obtaining and maintaining patent protection and regulatory approval for medical devices.